PDE-5 inhibitors
may cure
Pulmonary hypertension
PDE-5 inhibitors
may cure
Pulmonary hypertension
7.7
ValidityScore
Valid or Invalid?
-
2010Systematic Review
-
Jeremy P Feldman, Laura M Wicks, Mitchell S Buckley, Robin L Staib -
«CONCLUSION: Among the therapies currently available for the treatment of PAH, the PDE-5 inhibitors are a safe, effective, and well-tolerated therapeutic option. Sildenafil and tadalafil are FDA-approved for the treatment of PAH without respect to functional class. However, there is a paucity of data regarding vardenafil in PAH, and its use cannot be currently recommended. Whether as upfront therapy or ad-on therapy, a solid body of research now supports sildenafil and tadalafil as key treatments in PAH.»
-
-
2019
-
Barnes H, Brown Z, Burns A, Williams T -
«Background: Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated pulmonary artery pressure, and which left untreated lead to right-heart failure and death. PH includes World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH); Group 2 consists of PH due to left-heart disease (PH-LH); Group 3 comprises PH as a result of lung diseases or hypoxia, or both; Group 4 includes PH due to chronic thromboembolic occlusion of pulmonary vasculature (CTEPH), and Group 5 consists of cases of PH due to unclear and/or multifactorial mechanisms including haematological, systemic, or metabolic disorder. Phosphodiesterase type 5 (PDE5) inhibitors increase vasodilation and inhibit proliferation.»
-
#Adult, Child, Endothelin Receptor Antagonists / therapeutic use, Hayley Barnes, Humans, Hypertension, Hypertension, Hypertension, MEDLINE, Meta-Analysis, NCBI, NIH, NLM, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, Numbers Needed To Treat, PMC6354064, Phosphodiesterase 5 Inhibitors / adverse effects, Phosphodiesterase 5 Inhibitors / therapeutic use*, Placebos / therapeutic use, PubMed Abstract, Pulmonary / drug therapy*, Pulmonary / etiology, Pulmonary / mortality, Quality of Life, Randomized Controlled Trials as Topic, Systematic Review, Trevor Williams, Walk Test, Zoe Brown, doi:10.1002/14651858.CD012621.pub2, pmid:30701543 -
-
2019Systematic Review
-
Andrew Burns, Cochrane Airways Group, Hayley Barnes, Trevor Williams, Zoe Brown -
«RESULTS: We included 36 studies with 2999 participants (with pulmonary hypertension from all causes) in the final review. Trials were conducted for 14 weeks on average, with some as long as 12 months. Two trials specifically included children.
CONCLUSIONS: PDE5 inhibitors appear to have clear beneficial effects in group 1 PAH. Sildenafil, tadalafil and vardenafil are all efficacious in this clinical setting, and clinicians should consider the side‐effect profile for each individual when choosing which PDE5 inhibitor to prescribe. -
-
2013
-
Julio D Duarte, Rebekah L Hanson, Roberto F Machado -
«CONCLUSION: Although WHO Group 1 PH is rare, the majority of research has been done in this group, yielding three pharmacological classes available for its treatment: PDE5 inhibitors, prostacyclin analogs and ERAs. However, the treatments available are not ideal. The only drug class that has displayed a mortality benefit, prostacyclin analogs, has a poor side-effect profile and requires difficult to use parenteral delivery methods. New treatments (including an oral prostacyclin analog) are under investigation and range from repurposed drugs that are used to treat other diseases, to treatments targeting novel pathways, to gene therapy.»
-
-
2004Systematic Review
-
Cochrane Airways Group, E Haydn Walters, Parthipan Kanthapillai -
«RESULTS: Four studies recruiting 77 participants met the inclusion criteria of the review. Two studies assessed the acute effects of sildenafil. Two small crossover study assessed the effects of long term administration. The 'acute effect' studies indicated that sildenafil has a pulmonary vasodilatory effect. The two crossover studies showed improvement in symptoms. One study showed improvement in fatigue domains from a validated health status questionnaire. Both crossover studies reported that the drug was well tolerated.
-
ranked
added it
5 months ago
on Jul 24, 2020